Amylin Pharmaceuticals Added to the NASDAQ-100 Index
January 09 2006 - 7:15AM
PR Newswire (US)
SAN DIEGO, Jan. 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (NASDAQ:AMLN) announced that, effective today, it has been
added to the NASDAQ-100 Index(R), which is composed of the 100
largest non-financial stocks on The NASDAQ Stock Market(R) based on
market capitalization and eligibility criteria. "We are pleased to
be included on the NASDAQ-100 Index and listed among the top
companies in the world," said Ginger L. Graham, President and CEO
of Amylin Pharmaceuticals, Inc. "It is particularly meaningful
following our company's successful transition to a fully commercial
organization in 2005 and the market adoption of our first-in-class
diabetes products BYETTA(R) and SYMLIN(R)." Amylin has a market
capitalization of $4.4 billion. About the NASDAQ-100 Index The
NASDAQ-100 Index, launched in January 1985, is one of the most
widely followed benchmarks in the world. The NASDAQ-100 Index
Tracking Stock represents ownership in the NASDAQ-100 Trust. The
Trust holds a portfolio of equity securities that compose the
NASDAQ-100 Index and aims to provide investment results that
generally correspond with the performance of the Index. NASDAQ(R)
is the largest electronic screen-based equity securities market in
the United States. With approximately 3,200 companies, it lists
more companies and, on average, trades more shares per day than any
other U.S. market. It is home to companies that are leaders across
all areas of business including technology, retail, communications,
financial services, transportation, media and biotechnology. About
Amylin Amylin Pharmaceuticals is a biopharmaceutical company
committed to improving lives through the discovery, development and
commercialization of innovative medicines. Amylin has developed and
gained approval for two first- in-class medicines for diabetes,
SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide)
injection. Amylin is located in San Diego, California with over
1000 employees nationwide. Further information on Amylin
Pharmaceuticals and its pipeline in metabolism is available at
http://www.amylin.com/ . This press release contains
forward-looking statements about Amylin, which involve risks and
uncertainties. The Company's actual results could differ materially
from those discussed due to a number of risks and uncertainties,
including risks that BYETTA and/or SYMLIN may not prove to be
important new therapeutic options or may be affected by unexpected
new data or technical issues, and risks and uncertainties inherent
in the drug discovery and development process. Commercial and
government reimbursement and pricing decisions, the pace of market
acceptance and any issues related to manufacturing and supply may
also affect the potential for BYETTA and/or SYMLIN. These and
additional risks and uncertainties are described more fully in the
Company's most recently filed SEC documents, including its Form
10-Qs. Amylin undertakes no duty to update these forward-looking
statements. DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Mark
Foletta, VP, Finance and CFO, Amylin Pharmaceuticals, Inc.,
+1-858-552-2200 Web site: http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024